19064974

Source:http://linkedlifedata.com/resource/pubmed/id/19064974

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0014257, umls-concept:C0018270, umls-concept:C0036525, umls-concept:C0087111, umls-concept:C0332293, umls-concept:C1266043, umls-concept:C1522484, umls-concept:C1801960
pubmed:issue	2
pubmed:dateCreated	2009-1-12
pubmed:abstractText	Metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation is an aggressive disease that is associated with poor outcomes to chemotherapy or immunotherapy. The utility of vascular endothelial growth factor (VEGF)-targeted therapy in patients with this disease is unknown.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates, http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab, http://linkedlifedata.com/resource/pubmed/chemical/sorafenib, http://linkedlifedata.com/resource/pubmed/chemical/sunitinib
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	1527-7755
pubmed:author	pubmed-author:AydinHakanH, pubmed-author:BukowskiRonald MRM, pubmed-author:ElsonPaulP, pubmed-author:GarciaJorge AJA, pubmed-author:GeorgeSabyS, pubmed-author:GolshayanAli RezaAR, pubmed-author:HengDaniel YDY, pubmed-author:MekhailTarek MTM, pubmed-author:RiniBrian IBI, pubmed-author:WoodLaura SLS, pubmed-author:ZhouMingM
pubmed:issnType	Electronic
pubmed:day	10
pubmed:volume	27
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	235-41
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:19064974-Adult, pubmed-meshheading:19064974-Aged, pubmed-meshheading:19064974-Aged, 80 and over, pubmed-meshheading:19064974-Antibodies, Monoclonal, pubmed-meshheading:19064974-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19064974-Antineoplastic Agents, pubmed-meshheading:19064974-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19064974-Benzenesulfonates, pubmed-meshheading:19064974-Carcinoma, Renal Cell, pubmed-meshheading:19064974-Drug Delivery Systems, pubmed-meshheading:19064974-Female, pubmed-meshheading:19064974-Humans, pubmed-meshheading:19064974-Indoles, pubmed-meshheading:19064974-Kidney Neoplasms, pubmed-meshheading:19064974-Male, pubmed-meshheading:19064974-Middle Aged, pubmed-meshheading:19064974-Neoplasm Metastasis, pubmed-meshheading:19064974-Pyridines, pubmed-meshheading:19064974-Pyrroles, pubmed-meshheading:19064974-Retrospective Studies, pubmed-meshheading:19064974-Treatment Outcome, pubmed-meshheading:19064974-Vascular Endothelial Growth Factor A
pubmed:year	2009
pubmed:articleTitle	Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
pubmed:affiliation	Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.
pubmed:publicationType	Journal Article